Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals worldwide. It offers Halaven and Lenvima, an anticancer agent; Aloxi, an antiemetic agent; Aricept, a treatment for Alzheimer's disease; Fycompa, an antiepileptic agent; Methycobal for peripheral neuropathy treatment; BELVIQ for anti-obesity treatment; and LYRICA for neuropathic pain treatment. The company also provides Lunesta, a non-benzodiazepine hypnotic agent for insomnia treatment; Pariet, a proton pump inhibitor; HUMIRA, a human anti-TNF-a monoclonal antibody; and epilepsy franchise products, including Zonegran, Zebinix, Fycompa, and Inovelo, which are antiepileptic agents. In addition, it offers Inovelon/BANZEL for the treatment of Lennox-Gastaut syndrome; Actonel, an osteoporosis treatment; and Stronger Neo-Minophagen C/Glycyron tablets for liver disease/allergic disease treatment. The company has strategic partnerships with Quintiles Inc. for developing six types of anticancer compound candidates; and Epizyme, Inc. to discover, develop, and commercialize therapeutics targeting EZH2, an epigenetic enzyme, for the treatment of lymphoma and other cancers in genetically defined patients. It also has collaboration agreement with Ono Pharmaceutical Co., Ltd. to develop Lenvima (lenvatinib mesylate), a multi-kinase inhibitor, as well as Opdivo, a human anti-human programmed cell death-1 monoclonal antibody, for the treatment of hepatocellular carcinoma; and Merck & Co., Inc. to develop and commercialize Lenvima. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.
Industry, Sector and Symbol
Stock Exchange OTCMKTS
Industry Private households
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ESALY
Previous Symbol
CUSIPN/A
Phone813-3817-3700
Debt
Debt-to-Equity Ratio0.26
Current Ratio2.20
Quick Ratio1.92
Price-To-Earnings
Trailing P/E Ratio52.01
Forward P/E Ratio45.58
P/E GrowthN/A
Sales & Book Value
Annual Sales$5.42 billion
Price / Sales4.64
Cash Flow$2.3732 per share
Price / Cash Flow35.72
Book Value$18.64 per share
Price / Book4.55
Profitability
EPS (Most Recent Fiscal Year)$1.63
Net Income$466.60 million
Net Margins10.54%
Return on Equity10.74%
Return on Assets6.26%
Miscellaneous
Employees10,456
Outstanding Shares296,570,000
Market Cap$25.14 billion
OptionableNot Optionable
Eisai (OTCMKTS:ESALY) Frequently Asked Questions
What is Eisai's stock symbol?
Eisai trades on the OTCMKTS under the ticker symbol "ESALY."
When is Eisai's next earnings date?
Has Eisai been receiving favorable news coverage?
Headlines about ESALY stock have trended positive this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Eisai earned a news impact score of 3.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 8.0 out of 10, indicating that recent media coverage is very likely to have an effect on the company's share price in the near term.
Who are some of Eisai's key competitors?
Some companies that are related to Eisai include INDUSTRIA DE DI/ADR (IDEXY), AIRBUS SE/ADR (EADSY), NK Lukoil PAO (LUKOY), JAPAN TOB INC/ADR (JAPAY), Bayerische Motoren Werke (BAMXF), Iberdrola (IBDRY), VINCI S A/ADR (VCISY), China Shenhua Energy (CSUAY), Recruit (RCRRF), PERNOD RICARD S/ADR (PDRDY), Sun Hung Kai Properties (SUHJY), SCHNEIDER ELEC /ADR (SBGSY), CK HUTCHISON HO/ADR (CKHUY), SEVEN & I HOLDI/ADR (SVNDY) and SANDS CHINA Ltd/ADR (SCHYY).
Who are Eisai's key executives?
Eisai's management team includes the folowing people:
- Mr. Haruo Naito, CEO, Representative Corp. Officer & Director (Age 71)
- Mr. Gary Hendler, Sr. VP & Pres of EMEA Region (Age 52)
- Dr. Lynn D. Kramer, VP and Chief Clinical Officer & Chief Medical Officer - Neurology Bus. Group (Age 68)
- Mr. Alexander Scott, VP, Chief Strategy Officer & Head of Strategy Dept. - Neurology Bus. Group
- Ms. Shaji Procida, VP and Pres & COO of Eisai Inc. (Age 47)
How do I buy shares of Eisai?
Shares of ESALY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Eisai's stock price today?
One share of ESALY stock can currently be purchased for approximately $84.77.
How big of a company is Eisai?
Eisai has a market capitalization of $25.14 billion and generates $5.42 billion in revenue each year. The company earns $466.60 million in net income (profit) each year or $1.63 on an earnings per share basis. Eisai employs 10,456 workers across the globe.
What is Eisai's official website?
How can I contact Eisai?
Eisai's mailing address is 4-6-10 Koishikawa Bunkyo-ku, Tokyo M0, 112-8088. The company can be reached via phone at 813-3817-3700.
MarketBeat Community Rating for Eisai (OTCMKTS ESALY)
MarketBeat's community ratings are surveys of what our community members think about Eisai and other stocks. Vote "Outperform" if you believe ESALY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ESALY will underperform the S&P 500 over the long term. You may vote once every thirty days.
